Stryker Co. (NYSE:SYK) Director Sells $78,993,998.08 in Stock

Stryker Co. (NYSE:SYK) Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Stryker Price Performance

SYK stock opened at $399.01 on Thursday. The business has a 50 day simple moving average of $376.87 and a 200-day simple moving average of $364.00. The company has a market capitalization of $152.11 billion, a P/E ratio of 51.42, a PEG ratio of 2.78 and a beta of 0.96. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company posted $3.46 EPS. As a group, equities analysts anticipate that Stryker Co. will post 13.5 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.84%. Stryker’s payout ratio is 43.30%.

Analyst Ratings Changes

Several analysts have recently issued reports on SYK shares. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Citigroup increased their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group boosted their price objective on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Piper Sandler reaffirmed an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Finally, Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $419.37.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SYK. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker in the 4th quarter valued at $25,000. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the period. Centricity Wealth Management LLC purchased a new position in Stryker during the fourth quarter worth about $30,000. BankPlus Trust Department purchased a new stake in Stryker in the 4th quarter valued at approximately $33,000. Finally, Darwin Wealth Management LLC acquired a new position in Stryker during the 3rd quarter worth approximately $36,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.